Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease

References

• Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis. 2006;65(5):564–72.
   PubMed Web of Science ®Google Scholar
• Ohta A, Yamaguchi M, Tsunematsu T, Kasukawa R, Mizushima H, Kashiwagi H, et al. Adult Still's disease: a multicenter survey of Japanese patients. J Rheumatol. 1990;17(8):1058–63.
   PubMed Web of Science ®Google Scholar
• Aydintug AO, D’Cruz D, Cervera R, Khamashta MA, Hughes GR. Low dose methotrexate treatment in adult Still's disease. J Rheumatol. 1992;19(3):431–5.
   PubMed Web of Science ®Google Scholar
• Scheinberg MA, Chapira E, Fernandes ML, Hubscher O. Interleukin 6: a possible marker of disease activity in adult onset Still's disease. Clin Exp Rheumatol. 1996;14(6):653–5.
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Kontzias A, Ward CM, Ogden NS. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?Nat Clin Pract Rheumatol. 2007;3(6):328–35.
   PubMedGoogle Scholar
• Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol. 2004;31(11):2189–98.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Sibilia J, Mariette X, Combe B; Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64(2):262–6.
   PubMed Web of Science ®Google Scholar
• Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, Burmester GR. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis. 2010;69(2):466–7.
   PubMed Web of Science ®Google Scholar
• de Boysson H, Février J, Nicolle A, Auzary C, Geffray L. Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence. Clin Rheumatol. 2013;32(1):141–7.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 2011;585(23):3699–709.
   PubMed Web of Science ®Google Scholar
• Sakai R, Nagasawa H, Nishi E, Okuyama A, Takei H, Kurasawa T, et al. Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol. 2012;31(3):569–74.
   PubMed Web of Science ®Google Scholar
• Suematsu R, Ohta A, Matsuura E, Takahashi H, Fujii T, Horiuchi T, et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2012;22(5):712–9.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21(1):92–6.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Ochi H, Yanai A, Yamashita H, Itoh K, Mimori A. Successful tocilizumab therapy for adult onset Still's disease with intractable conditions over ten years. Nihon Naika Gakkai Zasshi. 2010;99(1):130–2.
   PubMedGoogle Scholar
• Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617): 998–1006.
   PubMed Web of Science ®Google Scholar
• Bagnari V, Colina M, Ciancio G, Govoni M, Trotta F. Adult-onset Still's disease. Rheumatol Int. 2010;30(7):855–62.
   PubMed Web of Science ®Google Scholar
• Ostrowski RA, Tehrani R, Kadanoff R. Refractory adult-onset still disease successfully treated with abatacept. J Clin Rheumatol. 2011;17(6):315–7.
   PubMed Web of Science ®Google Scholar
• Bartoloni E, Alunno A, Luccioli F, Santoboni G, Gerli R. Successful treatment of refractory adult-onset Still's disease with anti-CD20 monoclonal antibody. Clin Exp Rheumatol. 2009;27(5):888–9.
   PubMed Web of Science ®Google Scholar
• Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol. 2010; 37(5):967–73.
   PubMed Web of Science ®Google Scholar
• Arlet JB, Le TH, Marinho A, Amoura Z, Wechsler B, Papo T, Piette JC. Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006;65(12):1596–601.
   PubMed Web of Science ®Google Scholar
• Kaneko K, Kaburaki M, Muraoka S, Tanaka N, Yamamoto T, Kusunoki Y, et al. Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis. 2010;13(4):e67–9.
   Web of Science ®Google Scholar
• Gianella S, Schaer DJ, Schwarz U, Kurrer M, Heppner FL, Fehr J, Seebach JD. Retinal microangiopathy and rapidly fatal cerebral edema in a patient with adult-onset Still's disease and concurrent macrophage activation syndrome. Am J Hematol. 2008;83(5):424–7.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959–64.
   PubMed Web of Science ®Google Scholar
• Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129(5):750–4.
   PubMed Web of Science ®Google Scholar
• Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.
   PubMed Web of Science ®Google Scholar
• Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol. 2009;21(3):224–30.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162–7.
   PubMed Web of Science ®Google Scholar